377 related articles for article (PubMed ID: 33597521)
21. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
[TBL] [Abstract][Full Text] [Related]
22. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
23. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
[TBL] [Abstract][Full Text] [Related]
24. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
[TBL] [Abstract][Full Text] [Related]
25. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
26. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
Gallichotte EN; Baric TJ; Yount BL; Widman DG; Durbin A; Whitehead S; Baric RS; de Silva AM
PLoS Pathog; 2018 Feb; 14(2):e1006934. PubMed ID: 29481552
[TBL] [Abstract][Full Text] [Related]
27. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
[TBL] [Abstract][Full Text] [Related]
28. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
Weiskopf D; Angelo MA; Bangs DJ; Sidney J; Paul S; Peters B; de Silva AD; Lindow JC; Diehl SA; Whitehead S; Durbin A; Kirkpatrick B; Sette A
J Virol; 2015 Jan; 89(1):120-8. PubMed ID: 25320311
[TBL] [Abstract][Full Text] [Related]
29. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
30. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Simmons M; Burgess T; Lynch J; Putnak R
Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
[TBL] [Abstract][Full Text] [Related]
32. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
Galula JU; Salem GM; Chang GJ; Chao DY
Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
[TBL] [Abstract][Full Text] [Related]
33. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Martinez DR; Metz SW; Baric RS
Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
[TBL] [Abstract][Full Text] [Related]
34. Rapid Induction and Maintenance of Virus-Specific CD8
Graham N; Eisenhauer P; Diehl SA; Pierce KK; Whitehead SS; Durbin AP; Kirkpatrick BD; Sette A; Weiskopf D; Boyson JE; Botten JW
Front Immunol; 2020; 11():479. PubMed ID: 32265929
[TBL] [Abstract][Full Text] [Related]
35. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.
Metz SW; Tian S; Hoekstra G; Yi X; Stone M; Horvath K; Miley MJ; DeSimone J; Luft CJ; de Silva AM
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005071. PubMed ID: 27764114
[TBL] [Abstract][Full Text] [Related]
36. Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
Lin TH; Chen HW; Hsiao YJ; Yan JY; Chiang CY; Chen MY; Hu HM; Wu SH; Pan CH
Front Immunol; 2020; 11():546. PubMed ID: 32300346
[TBL] [Abstract][Full Text] [Related]
37. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
VanBlargan LA; Mukherjee S; Dowd KA; Durbin AP; Whitehead SS; Pierson TC
PLoS Pathog; 2013; 9(12):e1003761. PubMed ID: 24348242
[TBL] [Abstract][Full Text] [Related]
38. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
Kirkpatrick BD; Whitehead SS; Pierce KK; Tibery CM; Grier PL; Hynes NA; Larsson CJ; Sabundayo BP; Talaat KR; Janiak A; Carmolli MP; Luke CJ; Diehl SA; Durbin AP
Sci Transl Med; 2016 Mar; 8(330):330ra36. PubMed ID: 27089205
[TBL] [Abstract][Full Text] [Related]
39. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
40. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
Sun W; Eckels KH; Putnak JR; Lyons AG; Thomas SJ; Vaughn DW; Gibbons RV; Fernandez S; Gunther VJ; Mammen MP; Statler JD; Innis BL
J Infect Dis; 2013 Mar; 207(5):700-8. PubMed ID: 23225894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
